Significant agreements - AstraZeneca Collaboration Agreement (Details) $ in Thousands	1 Months Ended		12 Months Ended
	May 31, 2018 USD ($)	Nov. 30, 2016 item	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Aug. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Jun. 30, 2019 USD ($)
Significant agreements.
Collaboration revenues			$ 26,976	$ 14,463	$ 11,697
Deferred revenue			135,194	61,873	71,340
AstraZeneca
Significant agreements.
Option fee for development and exploitation rights	$ 5,000
Transaction price	5,700
Deferred revenue recognized			1,200
Collaboration revenues			1,204	1,165	1,404
Deferred revenue			$ 0	$ 1,076	$ 2,361
AstraZeneca | Target 3 Material Right
Significant agreements.
Deferred revenue related to the associated material rights								$ 1,500
AstraZeneca | Target 5 Material Right
Significant agreements.
Deferred revenue related to the associated material rights						$ 1,200
AstraZeneca | Target 6 Material Right
Significant agreements.
Deferred revenue related to the associated material rights							$ 1,100
AstraZeneca | Research and Development Milestone
Significant agreements.
Transaction price	700
AstraZeneca | 2016 Collaboration Agreement
Significant agreements.
Biological Targets | item		2
AstraZeneca | May 2018 Option Exercise
Significant agreements.
Option fee for development and exploitation rights	$ 5,000
Transaction price									$ 6,300